

1 Echocardiographic and Laboratory Findings in Coronary Slow Flow 2 Phenomenon: cross-sectional study and review

3 Mir Hosein Seyyed Mohammadzad¹, Salar Gardeshkhah², Kamal Khademvatani³, Amin Sedokani^{4*}

4

5 ¹Associated Professor of Interventional Cardiology, Cardiology Department, Medical Faculty, Urmia
6 University of Medical Sciences, Urmia, IRAN.

7 ² General Cardiologist, Cardiology Department, Medical Faculty, Urmia University of Medical Sciences,
8 Urmia, IRAN.

9 ³ Professor of Echocardiography, Cardiology Department, Medical Faculty, Urmia University of Medical
10 Sciences, Urmia, IRAN.

11 ⁴ Medical Doctor, Cardiology Department, Medical Faculty, Urmia University of Medical Sciences,
12 Urmia, IRAN.

13

14 **Correspondence:**

15 Amin Sedokani

16 Medical Doctor, Cardiology Department, Medical Faculty, Urmia University of Medical Sciences, Urmia,
17 IRAN.

18 Email: A.sedokani@gmail.com

19 Address: 17 Sharivar St., Urmia, IRAN (Postal Code: 571478334)

20 Phone: +98 443237 5907

21 Fax: +98 443 237 2917

22 **Abstract**

23 **Background and aims** Coronary Slow flow is a phenomenon known as slow
24 contrast flow that injected into the coronary arteries, without epicardial coronary
25 arteries obstruction. The etiology of this disease is unknown. Endothelial
26 dysfunction, known as a major cause of Coronary Slow flow syndrome (CSF).

27 **Methods:** This study was cross-sectional (descriptive-analytic), which was
28 performed on patients admitted to Seyedoshohada Heart Center, during one year
29 (2018-2019). Considering the inclusion and exclusion criteria, patients were
30 divided into two groups of normal coronary arteries (NECA, as the control group)
31 and with the Coronary slow-flow (CSF).

32 **Results:** In the present study, 124 patients were studied, 67.9% in the coronary
33 slow flow group and 39.4% in the control group were men ($p=0.001$). In the
34 coronary slow flow group, the mean age of patients was 52.18 ± 12.55 years and in
35 the control group, the mean age was 51.77 ± 10.36 years ($p=0.18$). Mean BMI was
36 significantly higher in the coronary slow flow group than the control group (p
37 <0.05). The smoking, hypertension, and mean of Lymphocyte, Hb, Hct, Plt, MPV,
38 RDW, BUN, FBS, TG, TC, LDL was significantly higher coronary slow flow
39 group. Also, in echocardiography, the mean E wave, E/A ratio was significantly
40 lower in the coronary slow flow group. The GLS was also significantly lower in
41 the control group ($p=0.01$). LAD was the most common type of coronaries that
42 involved with a slow flow.

43 **Conclusion:** The results of this study showed that there was a significant increase
44 in the rate of coronary slow flow in men, smokers, high BMI, and hypertensive
45 patients. Also, platelet count, MPV, LDL, FBS, and some laboratory variables
46 were high in patients with CSF. Mild diastolic dysfunction and low GLS were
47 observed in this group of patients.

48 **Keywords**

49 Coronary Angiography, Echocardiography, Coronary Slow flow, Laboratory findings

50 **1. Introduction**

51 The coronary slow flow phenomenon (CSFP or cardiac syndrome Y) refers to
52 delayed distal vessel contrast filling in angiography in normal or near-normal
53 coronary arteries that may present in one or all of coronary arteries (1-3). The
54 etiology of the disease is unknown, but histological studies of myofibers
55 hypertrophy, thickening of small vascular muscles with swelling, endothelial cell
56 degradation, and vascular lumen narrowing in these patients (4, 5). The CSFP is
57 diagnosed by Thrombolysis in Myocardial Infarction (TIMI) or the Corrected
58 TIMI Frame Count (CTFC) (6, 7). With advances in transthoracic
59 echocardiography, the pattern of LAD^a artery flow can be determined without
60 invasive measures. The accuracy of this method is more than 92% for LAD flow.
61 Patients with CSFP have low diastolic velocity in LAD. This method can also be
62 used to follow up on the treatment of patients (8-10). The prevalence of CSFP is 1-
63 7% of angiographies. 4% of patients with unstable angina are CSF^b patients. The
64 incidence of CSFP is also higher in young men and smokers (5, 11). These patients
65 suffer from recurrent chest pain, frequent hospitalization, and repeated cardiac
66 catheterization. Most importantly, life-threatening arrhythmias (sudden QTc^c
67 dispersion) have been reported in these patients. CSF can also lead to myocardial
68 ischemia and acute coronary syndrome (12-14).

69 Despite many studies, there is no certain explanation for the exact mechanism of
70 CSFP (1-4, 13, 15). It has been reported that there is a decrease in flow-mediated
71 dilatation (FMD) of brachial artery endothelium in CSF patients indicating
72 endothelial dysfunction (16). Increased plasma homocysteine and dimethylarginine
73 levels have also been observed in these patients, which in association with

^a Left Anterior Descending artery

^b Coronary Slow Flow

^c Corrected QT Interval

74 decreased nitric oxide (NO) levels may impair endothelial function (17, 18).
75 Studies have shown that the metabolic syndrome was higher in CSF patients with
76 high cholesterol, high fasting glucose, and high BMI. Insulin resistance and
77 impaired glucose tolerance have also been reported in these patients (19, 20).
78 Another possible cause of this syndrome is the role of the small vessels that are
79 resistive and have a diameter below $400^{\mu\text{m}}$. These vessels control myocardial blood
80 flow without clear stenosis in the epicardial artery. Some studies have suggested
81 fibromuscular hyperplasia, medial hypertrophy, myo-intimal proliferation,
82 endothelial edema, etc. as possible causes of microvascular dysfunction seen in
83 patients with CSF (5). The use of IVUS^d showed that in CSF patients, there was an
84 increase in intimal thickness and diffuse coronary calcification. These findings
85 suggest that CSFP may be a non-obstructive atherosclerotic disease that needs
86 further investigation (21). Also, inflammation that manifests itself with increased
87 CRP, IL-6, WBC, etc. and anatomical factors (geometrical motions, coronary
88 angles, bifurcation, etc.) can cause CSFP (22, 23).

89 Two-dimensional Speckle Tracking Echocardiography (STE) is a new imaging
90 method that, like tissue Doppler imaging (TDI), can calculate offline myocardial
91 velocities and deformation parameters such as strain rate (SR). the global
92 longitudinal strain (GLS) is also a robust, valid and repeatable technique for
93 measuring left ventricular deformation by echocardiography. The GLS appears to
94 be a sensitive method for the subclinical investigation of myocardial abnormalities
95 that can analyze and treat regional and generalized wall defects (24, 25). Recent
96 studies have shown that the study of total wall tension (GLS) by the STE method
97 can even reveal the most minor wall changes in people with normal LVEF (26).
98 Altunkas et al. showed that left ventricular systolic and diastolic function

^d Intravascular Ultrasonography

99 decreased in patients with the CSF while no change in right ventricular function
100 was observed and these changes can be monitored by the TDI/GLS method (27). In
101 other studies, with emphasis on TDI/GLS evaluation in patients with the CSF, they
102 reported impaired left ventricular systolic and diastolic function in patients with
103 CSF (by 2D/TDI) (28). Various studies have examined some aspects of the
104 involvement in CSF, for example, studies of the TDI/GLS echocardiography and
105 some other studies of clinical and laboratory predictors, risk factors, angiographic
106 profile, and clinical findings in CSFP (29-32). But so far, no study has
107 comprehensively investigated the laboratory and echocardiography findings of
108 CSF phenomenon in angiography.

109 In the present study, we aimed to investigate the comprehensive
110 echocardiographic, and laboratory findings in the patients with coronary slow flow
111 phenomenon in angiography.

112 **2. Material and Methods**

113 This study is a cross-sectional (descriptive-analytical) study that performed in a
114 year (August 2018- August 2019) in Seyedoshohada heart center of West
115 Azarbayjan province of Iran and 124 patients enrolled in the study. Patient
116 information was recorded in a pre-prepared checklist. Taking into account the
117 conditions of entry and exit of patients was divided into two separate groups of
118 normal epicardial coronary artery (NECA-as the control group) and coronary slow
119 flow (CSF) and then in the same conditions for both groups, the necessary
120 information for each group was separately completed.

121 In the present study, patients with normal systolic function entered the study. The
122 tests have been registered based on variables (such as WBC, Hb, Plt, MPV, RDW,
123 Cr, FBS, TG, TC, LDL, and HDL) in a pre-prepared checklist. Patients were also

124 subjected to echocardiography and their information was recorded separately in a
125 standard checklist previously prepared (including demographic, age, sex,
126 paraclinical and clinical information on underlying diseases, type of vessel
127 involved, etc.). The instrument for diagnosing and evaluating SCF patients was
128 coronary angiography, with TIMI greater than 27 and TIMI-2-Flow, which are
129 quantitative and qualitative methods of assessing coronary blood flow, respectively
130 (6, 11). Besides, after providing complete explanations about the study to the
131 participants, they were given informed consent and all information remained
132 confidential.

133 Exclusion criteria for the patients were the previous history of coronary heart
134 disease (including the history of stent implantation, history of CABG surgery, and
135 atherosclerotic coronary stenosis on a previous angiography), any significant
136 valvular heart disease, pulmonary hypertension, history of chronic obstructive
137 pulmonary disease (COPD), and atrioventricular conduction disturbances.

138 **2.1.Data Analysis**

139 The obtained information was expressed as mean, frequency and percentage. For
140 qualitative variables such as smoking, sex, family history, percentage, etc., and for
141 quantitative variables such as height, BMI, laboratory variables, mean±SD were
142 used. The quantitative variables were compared using Student t-test (Independent
143 Samples) or Mann-Whitney U test (depending on the type of data distribution).
144 The qualitative variables were analyzed using Chi-Square Test by SPSS V.26
145 software. In all of the test, the significance level was $P < 0.05$.

146 **2.2.Ethical statement**

147 All of the stages of the study were under supervision and confirmation of the
148 ethical committee of Seyedoshohada heart center and Urmia University of Medical
149 Sciences. After all the patients were provided with written and oral explanations,

150 they received written consent (informed written consent was given prior to the
151 inclusion of subjects in the study). All patients had the opportunity to withdraw
152 from the study at any time. Patient information remained confidential. There was
153 not any intervention or extra cost to patients. The special approved ethical code for
154 the study from ethics committee of Ministry of Health of Iran is
155 [IR.UMSU.REC.1397.236](https://doi.org/10.1101/2020.07.03.20145995). The investigation has met the principles outlined in the
156 Declaration of Helsinki.

157 **3. Results**

158 **4.1. Gender**

159 In the present study, 124 patients were examined that in the CSF group, 67.9% (36
160 people) were male and 32.1% (17 people) were female, and in the control group,
161 39.4% (26 people) were male and 60.6% (43 people) are women. Test results
162 showed that there was a significant relationship between coronary artery blood
163 flow and sex, and the frequency of men in the coronary artery blood flow group
164 was higher than the control group ($p=0.001$).

165 **4.2. Age**

166 In the CSF group, the average age of the patients 55.12 ± 18.52 years, the youngest
167 patient was 26 and the oldest one is 74 years old. In the control group, the mean
168 age was 51.77 ± 10.36 years, the youngest person was 27 years old and the oldest
169 was 72 years old. There was no significant difference between the mean age in the
170 coronary blood flow group and the control group ($p=0.18$).

171 **4.3. Family History of Coronary Heart Disease**

172 Our results indicated that, in the CSF group, 35.8% and in NECA, 21.1% had a
173 positive family history for coronary heart disease, but the difference was not
174 significant ($p=0.10$).

175 **4.4. Body Mass Index**

176 In the CSF group, mean BMI equal to 28.13 ± 2.28 kg/m², the lowest amount equal
177 to 23 and the maximum amount equal to 33 kilograms per square meter. In the
178 control group, the mean BMI was 24.58 ± 1.64 kg/m², the lowest value was 21 and
179 the highest value was 29 kg/m². The mean BMI in the CSF group was significantly
180 higher than the control group (P <0.001).

181 **4.5. Smoking**

182 In the CSF group, 62.2% (33 patients) of patients were active smokers while in the
183 NECA group this ratio was 18.3% (13 patients). The active smokers were more
184 frequent in the CSF group significantly (P <0.001).

185 **4.6. Hypertension**

186 The frequency of HTN among CSF and control group patients were as 58.5% and
187 25.4% respectively. The results indicated that HTN in CSF patients is significantly
188 more than NECA patients (P <0.001).

189 **4.7. Diabetes, Dyslipidemia, and Chronic Kidney Diseases**

190 In the assessment of diabetes mellitus, dyslipidemia, and CKD, our results
191 indicated that there were no significant differences in the mentioned diseases with
192 CSF phenomenon among groups for the p-values were 0.91, 0.49, and 0.65
193 respectively.

194 **4.8. Laboratory Findings**

195 An independent t-test was used to investigate the association of coronary artery
196 flow with laboratory parameters. The results show that the mean of Neutrophil
197 absolute count, Lymphocyte absolute count, Hct, Plt, MPV, RDW, Cr, TG, TC,
198 LDL in the CSF blood flow group is significantly higher than the control group
199 (Table 1, Figure 1).

200 **4.9. Echocardiographic Findings**

201 An independent t-test was also used to investigate the association between
202 coronary slow blood flow and echocardiographic parameters. Our results showed
203 that LVEF, IVSD, E wave, and LV systolic GLS are significantly higher in the
204 NECA group (Table 1).

205 **4.10. Artery Type**

206 In our study, 46.8% of the CSF arteries were on LAD, 27.9% were on LCX and
207 25.3% were on RCA. Due to this LAD was the most common artery with CSF
208 phenomenon.

209 **4.11. Global Longitudinal Strain for LV Function**

210 The results of the independent t-test show that the mean LV systolic GLS is
211 significantly higher in the NECA group than the CSF group ($p=0.01$, Table 1).

212 **4. Discussion**

213 The CSF blood flow is an angiographic diagnosis of slow-flowing contrast material
214 in normal or near-normal vessels in coronary epicardial vessels (1-3). The CSF
215 mimics a variety of clinical manifestations, including unstable angina, acute
216 myocardial infarction, and ventricular tachycardia (33). The exact cause and
217 mechanism of its pathophysiology are not yet known, but various studies have
218 suggested various hypotheses, including endothelial dysfunction, microvascular
219 dysfunction, early-stage coronary atherosclerosis, metabolic disorders, and
220 inflammatory disease (34-39). Researchers have observed in biopsies of patients
221 with CSF, fibromuscular hyperplasia, medial hypertrophy, myointimal
222 proliferation, endothelial edema, and degeneration in small vessels (5, 34). At
223 present, obstructive coronary artery disease has been suggested as a possible cause
224 (5). It has recently been reported that decreased adiponectin concentrations and the

225 activity of paraoxonase, two important markers of endothelial dysfunction, are
226 associated with CSF (40).

227 In the present study, in the CSF group, the mean age of the patients was higher
228 than the control group. Also, in the CSF group, most of the patients were male, and
229 in terms of gender, the prevalence of men was significantly higher in this group
230 than in the control group. In many similar studies, no significant difference in age
231 was observed among patients, but in terms of prevalence, the CSF was higher in
232 men (28-32, 41, 42). It can be said that based on the present study and other
233 studies, age cannot affect the mechanism of the CSF phenomenon, or at least more
234 detailed information can be provided by conducting further studies with a long
235 research period and several angiographic studies. Gender-oriented pathophysiology
236 has not yet been proposed. It may be due to hormonal changes, stressful situations,
237 or different job situations.

238 In this study, BMI was significantly higher in patients with the CSF than in the
239 control group, and a decrease in BMI could reduce the incidence of CSF in
240 patients. The results obtained are almost similar to the results of most studies
241 conducted in this field (29, 30, 32, 42). Although Sanati et al.'s study reported that
242 low BMI was associated with the CSFP (42). But other studies, including Yilmaz
243 et al., in a study of Turkish society, showed that high BMI had an independent
244 association with the CSF (19), and similarly Hawkins et al. showed that BMI was
245 an independent predictor for the CSF in the North American population (43).
246 Obesity can lead to endothelial dysfunction and can play a role in the CSF
247 pathogenesis, as Pontiroli et al, showed that after gastric banding procedure, BMI
248 decreased and improved endothelial system function (44). BMI is a predictor of
249 CSF in the population, so other studies are needed to show a link between lowering
250 BMI and improving CSF.

251 In the present study, smoking and high blood pressure were significantly higher in
252 patients with the CSF, but no difference was observed between the two groups in
253 terms of diabetes, dyslipidemia, and family history of coronary heart disease. In
254 some studies, there was no significant difference between the two groups in terms
255 of diabetes, blood pressure, dyslipidemia and family history of coronary heart
256 disease (32), while in others there was a significant relationship in terms of
257 smoking, blood pressure or the frequency of smokers and people with high blood
258 pressure in patients with CSF (28, 29, 41, 42)

259 The risk factors or pathophysiology of the CSF have not yet been fully elucidated,
260 and indifferent studies based on different populations and cultures; they are
261 exposed to various risk factors. As the results of the above studies confirmed. In
262 one study in Australia, the most important risk factors for the CSF were smoking
263 and male sex (2). However, in another study in China, hyperuricemia,
264 hyperglycemia, and high hsCRP have been identified as factors that cause
265 endothelial dysfunction as independent risk factors for the CSF (45). In the study
266 of Moazenzadeh et al, diabetes, hypertension, and opioid use were risk factors for
267 the CSF (46). Different populations (genetic differences) have different risk factors
268 for the occurrence of the CSF, so it can be said that one or more of these risk
269 factors may play a role in the development of the CSF by causing endothelial
270 system disorders.

271 The results of the present study showed that the mean of Lymphocyte, Hb, Hct, Plt,
272 MPV, RDW, BUN, FBS, TG, Total Cholesterol, LDL in the CSF blood flow group
273 was significantly higher than the control group. While the mean Neutrophil and
274 HDL in the coronary artery blood flow group were significantly lower than the
275 control group and there was no significant difference in terms of WBC and

276 Creatinine. Laboratory results, such as risk factors, can vary from patient to
277 patient.

278 In Yildiz et al.'s study, creatinine, uric acid, hematocrit, MCV, and HDL levels
279 were lower, but there was no significant difference between WBC, platelets,
280 fasting blood sugar, and MPV (28, 33, 42). In the study by Ghaffari et al., total
281 cholesterol, triglycerides, hemoglobin, hematocrit, lymphocytes count, platelet
282 count, platelet distribution, RDW, MPV, and fasting blood sugar were also
283 significantly higher in patients with the CSF. were higher in the CSF group, but
284 there was no difference in WBC, creatinine, monocytes, and neutrophils between
285 groups. Finally, it has been reported that people with the CSF may have an
286 underlying inflammation and endothelial dysfunction (29). Previous studies and
287 studies by Narimani et al. have highlighted high LDL and low HDL levels in
288 patients with the CSF blood flow (32), indicating that by modifying the fat profile
289 through diet, physical activity, or medication, the incidence of the CSF can be
290 reduced. However, like most of its mechanism is not clear at present. In some other
291 studies, there was no significant difference in hematocrit, platelet, uric acid,
292 HbA1C, homocysteine (30), and in general lipid profile and blood markers (31).
293 However, we need more research in this area.

294 In a study by Altun et al., the results showed that creatinine and hemoglobin levels
295 were high in CSF patients. MPV, RDW, and neutrophil-to-lymphocyte (N/L) ratios
296 did not differ significantly between the two groups. Inflammation has been shown
297 to play an important role in the CSF pathogenesis. However, the association of the
298 CSF with inflammatory markers is controversial (41). In some other studies, there
299 has been a strong association between RDW and inflammatory markers (47).
300 Studies have also shown that high RDW is associated with the CSF (48).

301 Platelet dysfunction can also play a role in the CSF pathogens. Gokce et al.
302 Showed that platelet aggregation was higher in patients with the CSF than in
303 controls. Therefore, it can be suggested that one of the possible causes of the
304 pathophysiology of the CSF can be platelet dysfunction. The size of the platelets
305 shown by the MPV is a useful marker for platelet function. And it has been shown
306 that MPV levels also have a significant positive association with the CSF (49, 50).

307 Examining the association of the CSF blood flow with echocardiographic
308 parameters, the results of the present study show that the mean, E wave, and E/A
309 ratio in the coronary blood flow group are significantly lower and DT is higher
310 than the control group, which can indicate mild diastolic disorder in patients with
311 the CSF. In Wang et al.'s study, the E/A ratios and E waves were significantly
312 reduced in CSF patients, yet there was no significant difference in terms of wave A
313 (28). Also, Baykan et al reported left ventricular systolic and diastolic disturbances
314 in patients with the CSF (51). In some studies, it has been suggested that in patients
315 with the CSFP, ischemic coronary artery disease may develop systolic and
316 diastolic left ventricular dysfunction (52-54). However, in the present study, the
317 only diastolic disturbance was observed and there was no significant difference in
318 terms of EF. However, the GLS of patients with the CSF was lower, which could
319 indicate physiological left ventricular dysfunction, which will be discussed below.
320 The levels of LVEF, IVSD, LVESD, LVEDD, and A wave did not differ
321 significantly between the CSF and the NECA groups. In the study of Narimani et
322 al. In terms of LVESD, LVEDD, EF, E and A waves, E/A ratio, DT, IVRT, there
323 was no significant difference between the two groups, but e and s' lateral wall
324 waves were lower in patients the CSF (32) but in another study, there was no
325 difference in LVEF (28).

326 By measuring GLS, we are able to measure myocardial movements in all
327 directions, and this criterion gives us the amount of left ventricular tension at all
328 angles (longitudinal, radial, and marginal). This completely non-invasive method is
329 very helpful in diagnosing and evaluating systolic and diastolic myocardial
330 function (55). GLS is a sensitive device for diagnosing left ventricular dysfunction
331 at the onset of many myocardial pathological conditions (39, 56). In the present
332 study, the mean GLS in the CSF blood flow group was significantly lower than the
333 control group. Wang et al. Reported that left ventricular diastolic and systolic
334 longitudinal traction was lower in patients with the CSF than in the control group
335 (28). However, in the study of Narimani et al., No statistically significant
336 relationship was observed in terms of systolic and diastolic longitudinal traction
337 and showed that the CSF could not impair systolic and diastolic longitudinal
338 function (32). Nurkalem and colleagues also showed that the left ventricular and
339 left ventricular longitudinal strain was different between the two groups (57).
340 There are controversies in left ventricular function in patients with CSF, so further
341 studies are needed. It has previously been shown that left ventricular longitudinal
342 traction impairment is affected earlier than marginal and radial traction (58).

343 In the present study, LAD was more common in terms of abundance of coronary
344 arteries in terms of the CSF, followed by LCX and RCA. In Yildiz et al.'s study,
345 the prevalence of the CSF in the LAD artery was also higher (42). Also, in other
346 similar studies, LAD, LCX, and RCA had the highest prevalence in terms of the
347 prevalence of the CSF (28, 30, 31). The prevalence of the CSF in different arteries
348 can vary widely in different technical and racial contexts, and the variable involved
349 in each vascular study. However, LAD was the most prevalent in most studies.

350 The results of the present study showed that in men, smokers, patients with high
351 BMI, and hypertension, the prevalence of Coronary Slow Flow was significantly

352 high. Also, platelet counts, MPV, LDL, FBS and some laboratory variables were
353 high in patients with slow coronary flow. In addition, in echocardiography, mild
354 diastolic disturbance and decreased left ventricular GLS were found in the
355 Coronary Slow Flow patients.

356 **5. Conflict of Interest**

357 **6. All of authors report no kind of conflict of interests in this study**
358 **and there is nothing**

359 **7. Financial Support**

360 This study was funded by Urmia University of Medical Sciences and there is no
361 other organizational or governmental funding.

362 **8. Author contributions**

363 All of the authors in this study have contributed equally in design, performance,
364 data collection, analysis, and writing and review of the manuscript.

365 **9. Acknowledgements**

366 We would like to thank the health care personnel of Seyedoshohada heart center,
367 specially the angiography and echocardiography ward personnel.

368 **10. References**

- 369 1. Kopetz V, Kennedy J, Heresztyn T, Stafford I, Willoughby SR, Beltrame JF. Endothelial function, oxidative
370 stress and inflammatory studies in chronic coronary slow flow phenomenon patients. *Cardiology*. 2012;121(3):197-
371 203.
- 372 2. Beltrame JF, Limaye SB, Horowitz JD. The coronary slow flow phenomenon--a new coronary microvascular
373 disorder. *Cardiology*. 2002;97(4):197-202.
- 374 3. Tambe AA, Demany MA, Zimmerman HA, Mascarenhas E. Angina pectoris and slow flow velocity of dye in
375 coronary arteries--a new angiographic finding. *Am Heart J*. 1972;84(1):66-71.
- 376 4. Caglayan AO, Kalay N, Saatci C, Yalcyn A, Akalyn H, Dundar M. Lack of association between the Glu298Asp
377 polymorphism of endothelial nitric oxide synthase and slow coronary flow in the Turkish population. *Can J Cardiol*.
378 2009;25(3):e69-72.

- 379 5. Mosseri M, Yarom R, Gotsman MS, Hasin Y. Histologic evidence for small-vessel coronary artery disease in
380 patients with angina pectoris and patent large coronary arteries. *Circulation*. 1986;74(5):964-72.
- 381 6. Gibson CM, Cannon CP, Daley WL, Dodge JT, Jr., Alexander B, Jr., Marble SJ, et al. TIMI frame count: a
382 quantitative method of assessing coronary artery flow. *Circulation*. 1996;93(5):879-88.
- 383 7. Kaski JC, Eslick GD, Merz CNB. *Chest Pain with Normal Coronary Arteries: A Multidisciplinary Approach*:
384 Springer Science & Business Media; 2013.
- 385 8. Citro R, Voci P, Pizzuto F, Maione AG, Patella MM, Bossone E, et al. Clinical value of echocardiographic
386 assessment of coronary flow reserve after left anterior descending coronary artery stenting in an unselected
387 population. *J Cardiovasc Med (Hagerstown)*. 2008;9(12):1254-9.
- 388 9. Tani T, Tanabe K, Kitai T, Yamane T, Kureha F, Katayama M, et al. Detection of severe stenosis and total
389 occlusion in the left anterior descending coronary artery with transthoracic Doppler echocardiography in the
390 emergency room. *Echocardiography*. 2009;26(1):15-20.
- 391 10. Anjaneyulu A, Raghu K, Chandramukhi S, Satyajit GM, Arramraja S, Raghavaraju P, et al. Evaluation of left
392 main coronary artery stenosis by transthoracic echocardiography. *J Am Soc Echocardiogr*. 2008;21(7):855-60.
- 393 11. Diver DJ, Bier JD, Ferreira PE, Sharaf BL, McCabe C, Thompson B, et al. Clinical and arteriographic
394 characterization of patients with unstable angina without critical coronary arterial narrowing (from the TIMI-III
395 Trial). *Am J Cardiol*. 1994;74(6):531-7.
- 396 12. Beltrame JF, Limaye SB, Wuttke RD, Horowitz JD. Coronary hemodynamic and metabolic studies of the
397 coronary slow flow phenomenon. *Am Heart J*. 2003;146(1):84-90.
- 398 13. Li JJ, Xu B, Li ZC, Qian J, Wei BQ. Is slow coronary flow associated with inflammation? *Med Hypotheses*.
399 2006;66(3):504-8.
- 400 14. Cutri N, Zeitz C, Kucia AM, Beltrame JF. ST/T wave changes during acute coronary syndrome presentation in
401 patients with the coronary slow flow phenomenon. *Int J Cardiol*. 2011;146(3):457-8.
- 402 15. Sezgin AT, Sigirci A, Barutcu I, Topal E, Sezgin N, Ozdemir R, et al. Vascular endothelial function in patients
403 with slow coronary flow. *Coron Artery Dis*. 2003;14(2):155-61.
- 404 16. Spiro JR, Digby JE, Ghimire G, Mason M, Mitchell AG, Ilsley C, et al. Brachial artery low-flow-mediated
405 constriction is increased early after coronary intervention and reduces during recovery after acute coronary
406 syndrome: characterization of a recently described index of vascular function. *Eur Heart J*. 2011;32(7):856-66.
- 407 17. Riza Erbay A, Turhan H, Yasar AS, Ayaz S, Sahin O, Senen K, et al. Elevated level of plasma homocysteine in
408 patients with slow coronary flow. *Int J Cardiol*. 2005;102(3):419-23.
- 409 18. Selcuk MT, Selcuk H, Temizhan A, Maden O, Ulupinar H, Baysal E, et al. Asymmetric dimethylarginine plasma
410 concentrations and L-arginine/asymmetric dimethylarginine ratio in patients with slow coronary flow. *Coron Artery*
411 *Dis*. 2007;18(7):545-51.
- 412 19. Yilmaz H, Demir I, Uyar Z. Clinical and coronary angiographic characteristics of patients with coronary slow
413 flow. *Acta Cardiol*. 2008;63(5):579-84.

- 414 20. Ozcan T, Gen R, Akbay E, Horoz M, Akcay B, Genctoy G, et al. The correlation of thrombolysis in myocardial
415 infarction frame count with insulin resistance in patients with slow coronary flow. *Coron Artery Dis.*
416 2008;19(8):591-5.
- 417 21. Cin VG, Pekdemir H, Camsar A, Cicek D, Akkus MN, Parmaksyz T, et al. Diffuse intimal thickening of
418 coronary arteries in slow coronary flow. *Jpn Heart J.* 2003;44(6):907-19.
- 419 22. Kalay N, Aytekin M, Kaya MG, Ozbek K, Karayakali M, Sogut E, et al. The relationship between inflammation
420 and slow coronary flow: increased red cell distribution width and serum uric acid levels. *Turk Kardiyol Dern Ars.*
421 2011;39(6):463-8.
- 422 23. Kantarci M, Gundogdu F, Doganay S, Duran C, Kalkan ME, Sagsoz ME, et al. Arterial bending angle and wall
423 morphology correlate with slow coronary flow: determination with multidetector CT coronary angiography. *Eur J*
424 *Radiol.* 2011;77(1):111-7.
- 425 24. Kalam K, Otahal P, Marwick TH. Prognostic implications of global LV dysfunction: a systematic review and
426 meta-analysis of global longitudinal strain and ejection fraction. *Heart.* 2014;100(21):1673-80.
- 427 25. Kurt M, Tanboga IH, Aksakal E. Two-Dimensional Strain Imaging: Basic principles and Technical
428 Consideration. *Eurasian J Med.* 2014;46(2):126-30.
- 429 26. Kaneko A, Tanaka H, Onishi T, Ryo K, Matsumoto K, Okita Y, et al. Subendocardial dysfunction in patients
430 with chronic severe aortic regurgitation and preserved ejection fraction detected with speckle-tracking strain
431 imaging and transmural myocardial strain profile. *Eur Heart J Cardiovasc Imaging.* 2013;14(4):339-46.
- 432 27. Altunkas F, Koc F, Ceyhan K, Celik A, Kadi H, Karayakali M, et al. The effect of slow coronary flow on right
433 and left ventricular performance. *Med Princ Pract.* 2014;23(1):34-9.
- 434 28. Wang Y, Ma C, Zhang Y, Guan Z, Liu S, Li Y, et al. Assessment of left and right ventricular diastolic and
435 systolic functions using two-dimensional speckle-tracking echocardiography in patients with coronary slow-flow
436 phenomenon. *PLoS One.* 2015;10(2):e0117979.
- 437 29. Ghaffari S, Tajlil A, Aslanabadi N, Separham A, Sohrabi B, Saeidi G, et al. Clinical and laboratory predictors of
438 coronary slow flow in coronary angiography. *Perfusion.* 2017;32(1):13-9.
- 439 30. Mukhopadhyay S, Kumar M, Yusuf J, Gupta VK, Tyagi S. Risk factors and angiographic profile of coronary
440 slow flow (CSF) phenomenon in North Indian population: An observational study. *Indian Heart J.* 2018;70(3):405-9.
- 441 31. Sanati H, Kiani R, Shakerian F, Firouzi A, Zahedmehr A, Peighambari M, et al. Coronary Slow Flow
442 Phenomenon Clinical Findings and Predictors. *Res Cardiovasc Med.* 2016;5(1):e30296.
- 443 32. Narimani S, Hosseinsabet A, Pourhosseini H. Effect of Coronary Slow Flow on the Longitudinal Left
444 Ventricular Function Assessed by 2-Dimensional Speckle-Tracking Echocardiography. *J Ultrasound Med.*
445 2016;35(4):723-9.
- 446 33. Saya S, Hennebry TA, Lozano P, Lazzara R, Schechter E. Coronary slow flow phenomenon and risk for sudden
447 cardiac death due to ventricular arrhythmias: a case report and review of literature. *Clin Cardiol.* 2008;31(8):352-5.
- 448 34. Mangieri E, Macchiarelli G, Ciavolella M, Barilla F, Avella A, Martinotti A, et al. Slow coronary flow: clinical
449 and histopathological features in patients with otherwise normal epicardial coronary arteries. *Cathet Cardiovasc*
450 *Diagn.* 1996;37(4):375-81.

- 451 35. Serne EH, de Jongh RT, Eringa EC, RG II, Stehouwer CD. Microvascular dysfunction: a potential
452 pathophysiological role in the metabolic syndrome. *Hypertension*. 2007;50(1):204-11.
- 453 36. Celebi H, Cataoglu AB, Kurtoglu H, Sener M, Hanavdelogullari R, Demiroglu C, et al. The relation between
454 coronary flow rate, plasma endothelin-1 concentrations, and clinical characteristics in patients with normal coronary
455 arteries. *Cardiovasc Revasc Med*. 2008;9(3):144-8.
- 456 37. Pekdemir H, Cin VG, Cicek D, Camsari A, Akkus N, Doven O, et al. Slow coronary flow may be a sign of
457 diffuse atherosclerosis. Contribution of FFR and IVUS. *Acta Cardiol*. 2004;59(2):127-33.
- 458 38. Li JJ, Qin XW, Li ZC, Zeng HS, Gao Z, Xu B, et al. Increased plasma C-reactive protein and interleukin-6
459 concentrations in patients with slow coronary flow. *Clin Chim Acta*. 2007;385(1-2):43-7.
- 460 39. Mor-Avi V, Lang RM, Badano LP, Belohlavek M, Cardim NM, Derumeaux G, et al. Current and evolving
461 echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement
462 on methodology and indications endorsed by the Japanese Society of Echocardiography. *J Am Soc Echocardiogr*.
463 2011;24(3):277-313.
- 464 40. Selcuk H, Selcuk MT, Temizhan A, Maden O, Saydam GS, Ulupinar H, et al. Decreased plasma concentrations
465 of adiponectin in patients with slow coronary flow. *Heart Vessels*. 2009;24(1):1-7.
- 466 41. Altun I, Akin F, Kose N, Sahin C, Kirli I. Predictors of slow flow in angiographically normal coronary arteries.
467 *Int J Clin Exp Med*. 2015;8(8):13762-8.
- 468 42. Yildiz A, Sezen Y, Gunebakmaz O, Kaya Z, Altiparmak IH, Erkus E, et al. Association of Meteorological
469 Variables and Coronary Blood Flow. *Clin Appl Thromb Hemost*. 2015;21(6):570-8.
- 470 43. Hawkins BM, Stavarakis S, Rousan TA, Abu-Fadel M, Schechter E. Coronary slow flow--prevalence and clinical
471 correlations. *Circ J*. 2012;76(4):936-42.
- 472 44. Pontiroli AE, Pizzocri P, Paroni R, Folli F. Sympathetic overactivity, endothelial dysfunction, inflammation, and
473 metabolic abnormalities cluster in grade III (World Health Organization) obesity: reversal through sustained weight
474 loss obtained with laparoscopic adjustable gastric banding. *Diabetes Care*. 2006;29(12):2735-8.
- 475 45. Xia S, Deng SB, Wang Y, Xiao J, Du JL, Zhang Y, et al. Clinical analysis of the risk factors of slow coronary
476 flow. *Heart Vessels*. 2011;26(5):480-6.
- 477 46. Moazenzadeh M, Azimzadeh BS, Zare J, Shokouhi M, Sheikhvatan M. Clinical features and main determinants
478 of coronary slow flow phenomenon in Iranian patients. *Eur J Cardiovasc Med*. 2010;1(2):2042.
- 479 47. Patel KV, Ferrucci L, Ershler WB, Longo DL, Guralnik JM. Red blood cell distribution width and the risk of
480 death in middle-aged and older adults. *Arch Intern Med*. 2009;169(5):515-23.
- 481 48. Luo SH, Jia YJ, Nie SP, Qing P, Guo YL, Liu J, et al. Increased red cell distribution width in patients with slow
482 coronary flow syndrome. *Clinics (Sao Paulo)*. 2013;68(6):732-7.
- 483 49. Gokce M, Kaplan S, Tekelioglu Y, Erdogan T, Kucukosmanoglu M. Platelet function disorder in patients with
484 coronary slow flow. *Clin Cardiol*. 2005;28(3):145-8.
- 485 50. Lanza G, Andreotti F, Sestito A, Sciahbasi A, Crea F, Maseri A. Platelet aggregability in cardiac syndrome X.
486 *European heart journal*. 2001;22(20):1924-30.

- 487 51. Baykan M, Baykan EC, Turan S, Gedikli O, Kaplan S, Kiris A, et al. Assessment of left ventricular function and
488 Tei index by tissue Doppler imaging in patients with slow coronary flow. *Echocardiography*. 2009;26(10):1167-72.
- 489 52. Demirkol MO, Yaymaci B, Mutlu B. Dipyridamole myocardial perfusion single photon emission computed
490 tomography in patients with slow coronary flow. *Coron Artery Dis*. 2002;13(4):223-9.
- 491 53. Buchthal SD, den Hollander JA, Merz CN, Rogers WJ, Pepine CJ, Reichek N, et al. Abnormal myocardial
492 phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary
493 angiograms. *N Engl J Med*. 2000;342(12):829-35.
- 494 54. Yaymaci B, Dagdelen S, Bozbuga N, Demirkol O, Say B, Guzelmeric F, et al. The response of the myocardial
495 metabolism to atrial pacing in patients with coronary slow flow. *Int J Cardiol*. 2001;78(2):151-6.
- 496 55. Biering-Sorensen T, Solomon SD. Assessing Contractile Function When Ejection Fraction Is Normal: A Case
497 for Strain Imaging. *Circ Cardiovasc Imaging*. 2015;8(11):e004181.
- 498 56. Yuda S, Fang ZY, Marwick TH. Association of severe coronary stenosis with subclinical left ventricular
499 dysfunction in the absence of infarction. *J Am Soc Echocardiogr*. 2003;16(11):1163-70.
- 500 57. Nurkalem Z, Gorgulu S, Uslu N, Orhan AL, Alper AT, Erer B, et al. Longitudinal left ventricular systolic
501 function is impaired in patients with coronary slow flow. *Int J Cardiovasc Imaging*. 2009;25(1):25-32.
- 502 58. Edvardsen T, Helle-Valle T, Smiseth OA. Systolic dysfunction in heart failure with normal ejection fraction:
503 speckle-tracking echocardiography. *Prog Cardiovasc Dis*. 2006;49(3):207-14.

504 **10. Figure Legends**

505 Figure 1. Laboratory data of the Coronary Slow Flow (53 patients) and Normal Epicardial
506 Coronary Artery Groups (71 patients). Student t-test, Error Bar Confidence Interval: 95%.

507 Figure 2. Echocardiographic findings of the Coronary Slow Flow (53 patients) and Normal
508 Epicardial Coronary Artery Groups (71 patients). Student t-test, Error Bar Confidence Interval:
509 95%.

510 Figure 3. Mean Left Ventricle Global Longitudinal Strain Comparison of the Coronary Slow
511 Flow (53 patients) and Normal Epicardial Coronary Artery Groups (71 patients). Student t-test,
512 Error Bar Confidence Interval: 95%.





